29810-09-1

Basic information

• Product Name: (R)-2-(diMethylaMino)-2-phenylaceticacid
• Synonyms: (R)-2-(diMethylaMino)-2-phenylaceticacid
• CAS NO: 29810-09-1
• Molecular Formula: C₁₀H₁₃NO₂
• Molecular Weight: 179.21572
• Mol File: 29810-09-1.mol
• Article Data: 15

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (R)-2-(diMethylaMino)-2-phenylaceticacid(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-(diMethylaMino)-2-phenylaceticacid(29810-09-1)
• EPA Substance Registry System: (R)-2-(diMethylaMino)-2-phenylaceticacid(29810-09-1)

Safety Data

• Hazardous Substances Data: 29810-09-1(Hazardous Substances Data)

Usage

Description

(R)-2-(dimethylamino)-2-phenylacetic acid, with the molecular formula C11H15NO2, is a chiral compound that possesses a non-superimposable mirror image. It is characterized by its structure, which includes a phenyl group, a carboxylic acid group, and a dimethylamino group. These structural features endow the compound with both acidic and basic properties, making it a versatile molecule with potential applications in various fields.

Uses

Used in Pharmaceutical Industry:
(R)-2-(diMethylaMino)-2-phenylacetic acid is used as a pharmaceutical compound for its potential anti-inflammatory and analgesic properties. Its unique structure allows it to modulate various biological pathways, making it a promising candidate for the development of new drugs to treat pain and inflammation.
Used in Organic Synthesis:
(R)-2-(diMethylaMino)-2-phenylacetic acid is used as a reagent in organic synthesis, where its acidic and basic properties facilitate the formation of new chemical bonds and the synthesis of complex molecules. Its chiral nature also makes it a valuable building block for the creation of enantiomerically pure compounds, which are essential in the development of many pharmaceuticals.
Used as a Chiral Auxiliary:
In the field of organic chemistry, (R)-2-(diMethylaMino)-2-phenylacetic acid is used as a chiral auxiliary. This application takes advantage of its ability to induce stereoselectivity in chemical reactions, leading to the preferential formation of one enantiomer over the other. This is particularly important in the synthesis of pharmaceuticals, where the desired biological activity is often associated with a specific enantiomer.
Used in the Synthesis of Various Pharmaceuticals:
(R)-2-(diMethylaMino)-2-phenylacetic acid is also utilized in the synthesis of a wide range of pharmaceuticals. Its unique structure and properties make it a valuable starting material or intermediate in the production of various drugs, contributing to the development of new treatments for a variety of medical conditions.

Upstream product

• 50-00-0 formaldehyd 
• 875-74-1 (R)-phenylglycine 
• 30925-14-5 (R)-(-)-α-methylamino phenylacetic acid 
• 4870-65-9 2-bromophenylacetic acid 
• 74641-60-4 2-methylamino-2-phenylacetic acid 
• 75-07-0 acetaldehyde 

Downstream Products

• 2202-65-5 (R)-2-(dimethylamino)-2-phenylethanol 
• 1007883-22-8 (1R,1'R)-2,2'-(4,4'-biphenyldiylbis(1H-imidazole-5,2-diyl-(4R)-1,3-thiazolidine-4,3-diyl))bis(N,N-dimethyl-2-oxo-1-phenylethanamine) 
• 1007882-34-9 (2R,2'R)-N,N'-(4,4'-biphenyl-diylbis(1H-imidazole-5,2-diyl(1S)-1,1-ethane-diyl))bis(2-(dimethyl-amino)-N-methyl-2-phenyl-acetamide) 
• 1007882-37-2 (2R)-2-(dimethyl-amino)-N-((1S)-1-(5-(4'-(2-((2S)-1-((2R)-2-(dimethyl-amino)-2-phenyl-acetyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)ethyl)-N-methyl-2-phenyl-acetamide 
• 74492-08-3 (R)-phenyl-glyphos 
• 2202-63-3 ((R)-2-Chloro-1-phenyl-ethyl)-dimethyl-amine; hydrochloride 
• 80376-23-4 trans-chloro(N,N-dimethyl-D-phenylglycine)(ethylene)platinum(II) 
• 1228214-95-6 (R)-3-[4-(4'-{2-[(S)-1-((R)-2-dimethylamino-2-phenyl-acetyl)-pyrrolidin-2-yl]-1H-imidazol-4-yl}-biphenyl-4-yl)-1H-imidazol-2-yl]-1,8-dioxa-4-aza-spiro[4.5]decane-4-carboxylic acid benzyl ester 
• 1228964-67-7 C₄₂H₄₄N₈O₄ 
• 1252600-83-1 methyl (S)-1-((S)-2-(4-(((4-((S)-1-((R)-2-(dimethylamino)-2-phenylacetyl)pyrrolidine-2-carboxamido)benzyl)(phenyl)amino)methyl)phenylcarbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-ylcarbamate 
• 1318898-60-0 methyl {(1S)-1-[((2S,4S)-2-{5-[6-(2-{(2S,4S)-1-[(2R)-2-(dimethylamino)-2-phenylacetyl]-4-methyl-2-pyrrolidinyl}-1H-imidazol-4-yl)-2-naphthalenyl]-1H-benzimidazol-2-yl}-4-methyl-1-pyrrolidinyl)carbonyl]-2-methylpropyl}carbamate 
• 1318898-85-9 methyl {(1S)-1-[((2S,4S)-2-{4-[6-(2-{(2S,4S)-1-[(2R)-2-(dimethylamino)-2-phenylacetyl]-4-methyl-2-pyrrolidinyl}-1H-benzimidazol-5-yl)-2-naphthalenyl]-1H-imidazol-2-yl}-4-methyl-1-pyrrolidinyl)carbonyl]-2-methylpropyl}carbamate 
• 1445591-53-6 (R)-1-((S)-2-(5-(4-bromophenyl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-2-(dimethylamino)-2-phenylethanone 
• 1017607-23-6 C₄₁H₄₇N₇O₃ 

Relevant articles and documents

Matched and mixed cap derivatives in the tetracyclic indole class of HCV NS5A inhibitors

A matched and mixed capping SAR study was conducted on the tetracyclic indole class of HCV NS5A inhibitors to examine the influence of modifications of this region on the overall HCV virologic resistance profiles.

SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to novel Silyl-Containing Heterocyclic Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, C, D, E, F and L are as defined herein. The present invention also relates to compositions comprising at least one Silyl-Containing Heterocyclic Compound, and methods of using the Silyl-Containing Heterocyclic Compounds for treating or preventing HCV infection in a patient.

TETRACYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to novel Tetracyclic Indole Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, A', G, R1, R15, U, V, V', X, X', Y and Y' are as defined herein. The present invention also relates to compositions comprisingat least one Tetracyclic Indole Derivative, and methods of using the Tetracyclic Indole Derivatives for treating or preventing HCV infection in a patient.